Literature DB >> 19467836

Percutaneous transluminal angioplasty of lower limb arteries causes a systemic inflammatory response.

Jitesh H Parmar1, Mo Aslam, Nigel J Standfield.   

Abstract

BACKGROUND: Percutaneous transluminal angioplasty (PTA) of a lower limb arterial segment is a well-established treatment for suitable lesions for critical or noncritical lower limb ischemia. Our aim was to define the inflammatory response after PTA by measuring inflammatory markers.
METHODS: Twenty-five patients having PTA were compared with 20 patients having angiography alone. Interleukin-6 (IL-6), IL-8, IL-10, and tumor necrosis factor-alpha (TNF-alpha) were measured sequentially. The difference between postprocedure and preprocedure baseline levels were compared statistically between angiography alone and PTA. Patients were followed up to 1 year after the procedure, and the failure rate of PTA was noted.
RESULTS: IL-6 and TNF-alpha were significantly higher in PTA patients at 1 hr after PTA (p < 0.05), and the IL-6 level only was significantly higher at 24 hr post-PTA (p < 0.05) compared to angiography alone (Mann-Whitney test). IL-8 and IL-10 levels did not differ significantly in the PTA group. At 1 year after the procedure, 45% of PTAs had failed. There was no statistically significant correlation between failed PTA and inflammatory response.
CONCLUSION: PTA appears to cause a significant inflammatory response compared to angiography alone. This demonstrates a systemic manifestation of localized ischemia/reperfusion injury. Further investigation of the inflammatory response due to ischemia/reperfusion injury and its correlation with restenosis is recommended.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19467836     DOI: 10.1016/j.avsg.2009.02.004

Source DB:  PubMed          Journal:  Ann Vasc Surg        ISSN: 0890-5096            Impact factor:   1.466


  5 in total

1.  Systemic inflammation as a predictor of clinical outcomes after lower extremity angioplasty/stenting.

Authors:  Kenneth DeSart; Kerri O'Malley; Bradley Schmit; Maria-Cecilia Lopez; Lyle Moldawer; Henry Baker; Scott Berceli; Peter Nelson
Journal:  J Vasc Surg       Date:  2015-06-06       Impact factor: 4.268

2.  Restenosis and therapy.

Authors:  Laszlo Denes; Laszlo Entz; Veronika Jancsik
Journal:  Int J Vasc Med       Date:  2012-02-23

3.  Impact of routine coronary catheterization in low extremity artery disease undergoing percutaneous transluminal angioplasty: study protocol for a multi-center randomized controlled trial.

Authors:  I-Chih Chen; Cheng-Han Lee; Ting-Hsing Chao; Wei-Kung Tseng; Tsung-Hsien Lin; Wen-Jung Chung; Jen-Kwan Li; Hsuan-Li Huang; Ping-Yen Liu; Ting-Kuang Chao; Chuin-Yuan Chu; Chih-Chan Lin; Po-Chao Hsu; Wen-Huang Lee; Po-Tseng Lee; Yi-Heng Li; Shih-Ya Tseng; Liang-Miin Tsai; Juey-Jen Hwang
Journal:  Trials       Date:  2016-02-29       Impact factor: 2.279

4.  Increased Plasma Cathepsin s at the Time of Percutaneous Transluminal Angioplasty is Associated with 6-months' Restenosis of the Femoropopliteal Artery.

Authors:  Mojca Bozic Mijovski; Vinko Boc; Ursa Pecar Fonovic; Janja Marc; Ales Blinc; Janko Kos; Darko Cerne
Journal:  J Med Biochem       Date:  2018-01-01       Impact factor: 3.402

5.  Batroxobin accelerated tissue repair via neutrophil extracellular trap regulation and defibrinogenation in a murine ischemic hindlimb model.

Authors:  Haruchika Masuda; Atsuko Sato; Tomoko Shizuno; Keiko Yokoyama; Yusuke Suzuki; Masayoshi Tokunaga; Takayuki Asahara
Journal:  PLoS One       Date:  2019-08-16       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.